ReviewPain and therapy2017
Pharmacotherapy for Neuropathic Pain: A Review.
Review in Pain and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06401499 (The Effect of Low Dose Pregabalin and Etoricoxib Combination on Pain in Comparison to Etoricoxib Alone in Patients Suffering From Chronic Low Back Pain), which is not on this map. Cited by 112 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Low Dose Pregabalin and Etoricoxib Combination on Pain in Comparison to Etoricoxib Alone in Patients Suffering From Chronic Low Back Pain
Who cites it
112 citing papers in PubMed, 3 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- The neuroprotective effects of progesterone against peripheral neuropathy: a systematic review of non-clinical studies.Metabolic brain disease · 2024Pooled it
- The effect of neuropathic pain treatments on pain interference following spinal cord injury: A systematic review.The journal of spinal cord medicine · 2024Pooled it
- Neuropathic pain in burn patients - A common problem with little literature: A systematic review.Burns : journal of the International Society for Burn Injuries · 2024Pooled it
- Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies.Pharmacological reports : PR · 2021Trial
- Sex-related analgesic responses to photobiomodulation therapy in rats with neuropathic pain.Lasers in medical science · 2026Article
- Relationships between dietary antioxidant capacity, systemic redox balance, and neuropathic pain after spinal cord injury.Spinal cord · 2026Article
- Neuropathic Pain Management Using Novel Biologics in Moderate-to-Severe Hidradenitis Suppurativa.Current pain and headache reports · 2026Review
- Untangling neuropathic pain: pathophysiological insights and future directions for targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Targeting druggable kinases in neuropathic pain.npj drug discovery · 2026Review
- A Systemically Administered Humanized Anti-Nav1.7 Antibody with Long-Lasting Analgesic Activity and Preserved Physiological Nociception.Pharmaceutics · 2026Article
- Recombinant dimeric PICK1 peptide inhibitors for long-term relief of chronic pain by AAV therapeutics.Cell reports. Medicine · 2026Article
- The Role of Vitamin D in Neuropathic Pain: Biological Mechanisms and Clinical Relevance.International journal of molecular sciences · 2026Review
- Review
- Phenylephrine per se or Combined with Pregabalin Ameliorates Mononeuropathic Pain in Rats.Pharmaceutics · 2026Article
- Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician.Pain medicine (Malden, Mass.) · 2026Review
- Antioxidant Therapy Reverses Sound Stress-Induced Opioid Resistance in a Mouse Model of Mechanical Allodynia.Journal of pain research · 2026Article
- Injectable Poloxamer and Hyaluronic Acid Hydrogel for Sustained Co-Delivery of Dexamethasone and Lidocaine Ameliorates Neuropathic Pain.Biomaterials research · 2026Article
- Traumatic Brain Injury and Depressive Symptoms in Community-Dwelling Older Adults: A Prospective Cohort Study.Neurology · 2025Article
- Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain.Biomolecules · 2025Article
- Psychotropic Medications for Non-Psychiatric Conditions: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain, comprising a range of heterogeneous conditions, is often severe and difficult to manage, and this may result in a chronic condition that negatively affects the overall functioning and quality of life in patients. The pharmacotherapy of neuropathic pain is challenging and for many patients effective treatment is lacking; therefore, evidence-based recommendations are essential. Currently, there is general agreement on which drugs are appropriate for the first-line treatment of neuropathic pain, whereas debate continues regarding second- and third-line treatments. First-line drugs for neuropathic pain include antidepressants (tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors) and anticonvulsants acting at calcium channels (pregabalin and gabapentin). Second- and third-line drugs for neuropathic pain include topical lidocaine and opioids. Although efficacious in the treatment of neuropathic pain, opioids are not considered to be a first choice because of adverse drug reactions and, more recently, because of concerns about abuse, diversion, and addiction. A clear understanding of the mechanism of action of currently available drugs is an essential step towards an effective clinical approach that aims to tailor therapies both to the specific neuropathic disease and to the needs of an individual patient. This review provides an overview of current drugs available for the treatment of neuropathic pain with an emphasis on their mechanism of action.
fundingPfizer, Italy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.